Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980
- PMID: 35768240
- PMCID: PMC9353855
- DOI: 10.3960/jslrt.22011
Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980
Abstract
The current consensus on Castleman disease is that it is a group of several distinct lymphoproliferative disorders with different underlying pathogenesis and clinical outcomes. In 1980, Mori et al. proposed the concept of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia (IPL), a disease of unknown etiology, characterized by severe polyclonal hypergammaglobulinemia and generalized superficial lymphadenopathy. After Frizzera et al.'s landmark report in 1983, the term multicentric Castleman disease (MCD) gradually became established, and for a time, IPL was regarded as identical to MCD. However, with the subsequent recognition of human herpesvirus 8 (HHV8)-related MCD in the 1990s and the contributions by Kojima et al. in the 2000s, in which non-HHV8-related MCD (now called idiopathic MCD) was at least subclassified into IPL and others (non-IPL), it is now clear that the original distinctiveness of IPL is still maintained in MCD, which is a diverse collection of diseases.
Keywords: IPL; MCD; TAFRO syndrome; iMCD; idiopathic plasmacytic lymphadenopathy.
Conflict of interest statement
CONFLICT OF INTEREST
The authors have no conflicts of interest directly relevant to the content of this article.
Figures



Similar articles
-
Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.Int J Mol Sci. 2022 Sep 7;23(18):10301. doi: 10.3390/ijms231810301. Int J Mol Sci. 2022. PMID: 36142213 Free PMC article.
-
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.Br J Haematol. 2024 May;204(5):1830-1837. doi: 10.1111/bjh.19334. Epub 2024 Feb 15. Br J Haematol. 2024. PMID: 38356434 Free PMC article.
-
TAFRO Syndrome: A Syndrome or a Subtype of Multicentric Castleman Disease?Biomedicines. 2024 Mar 14;12(3):652. doi: 10.3390/biomedicines12030652. Biomedicines. 2024. PMID: 38540266 Free PMC article.
-
Overview of Castleman disease.Blood. 2020 Apr 16;135(16):1353-1364. doi: 10.1182/blood.2019000931. Blood. 2020. PMID: 32106302 Review.
-
[Recent advances in diagnosis and treatment of idiopathic multicentric Castleman disease].Rinsho Ketsueki. 2019;60(9):1205-1211. doi: 10.11406/rinketsu.60.1205. Rinsho Ketsueki. 2019. PMID: 31597845 Review. Japanese.
Cited by
-
Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease.Int J Mol Sci. 2022 Sep 7;23(18):10301. doi: 10.3390/ijms231810301. Int J Mol Sci. 2022. PMID: 36142213 Free PMC article.
-
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis.Am J Hematol. 2025 Sep;100(9):1502-1512. doi: 10.1002/ajh.27743. Epub 2025 Jun 20. Am J Hematol. 2025. PMID: 40540535 Free PMC article.
-
Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease.J Clin Exp Hematop. 2022;62(2):58-59. doi: 10.3960/jslrt.22016. J Clin Exp Hematop. 2022. PMID: 35768239 Free PMC article. No abstract available.
-
Diagnostic challenges of the idiopathic plasmacytic lymphadenopathy (IPL) subtype of idiopathic multicentric Castleman disease (iMCD): Factors to differentiate from IgG4-related disease.J Clin Pathol. 2024 Feb 20:jcp-2023-209280. doi: 10.1136/jcp-2023-209280. Online ahead of print. J Clin Pathol. 2024. PMID: 38378248 Free PMC article.
-
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.Br J Haematol. 2024 May;204(5):1830-1837. doi: 10.1111/bjh.19334. Epub 2024 Feb 15. Br J Haematol. 2024. PMID: 38356434 Free PMC article.
References
-
- Wu D, Lim MS, Jaffe ES. Pathology of Castleman Disease. Hematol Oncol Clin North Am. 2018; 32: 37-52. - PubMed
-
- Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972; 29: 670-683. - PubMed
-
- Flendrig J. Benign giant lymphoma: Clinicopathologic correlation study. In: Clark R, Gumley R (eds): The Year Book of Cancer. Chicago, Year Book Medical Publishers. 1970; pp. 296-299.
-
- Case 40011. N Engl J Med. 1954; 250: 26-30. - PubMed
-
- Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer. 1956; 9: 822-830. - PubMed